

Roger Newton has been elected to the board of directors of Resverlogix (Calgary, Alberta, Canada) effective July 10, 2007. Dr. Newton has 25 years of experience in the pharma and life sciences industries, and currently serves as senior vice president of Pfizer global R&D and a director of Esperion Therapeutics. He was formerly cofounder, president and CEO of Esperion Therapeutics, which was acquired by Pfizer in 2003. Prior to cofounding Esperion, Dr. Newton was a scientist and chairman of the atherosclerosis drug discovery team at Warner-Lambert/Parke-Davis (now Pfizer) from 1981–1998, where he codiscovered and was the product champion of Lipitor (atorvastatin).

“I am very pleased to be joining the board of directors of Resverlogix,” says Dr. Newton. “It is a very exciting time for the NexVas Plaque Regression technology. We know that raising ApoA-I and functional HDL can regress atherosclerosis and this technology has the potential to be first in a new class of drugs for the treatment of cardiovascular disease due to atherosclerosis.”



Hana Biosciences (S. San Francisco, CA, USA) has announced the appointment of **Steven R. Deitcher** as executive vice president and chief medical officer. Dr. Deitcher most recently served

as vice president, chief medical scientist at Nuvelo, where he was responsible for clinical development and medical affairs. In addition, Hana also reported that **Greg Berk**, former vice president and chief medical officer, will be leaving the company to pursue other interests.

Innovive Pharmaceuticals (New York) has announced the appointment of **Philip Frost** to the company’s board of directors. Dr. Frost has more than 30 years of experience in the fields of cell biology and oncology pharmaceutical R&D. From 2005 to 2007, he served as executive vice president and CSO at ImClone Systems.



David Glover, who joined stem cell company VetCell Bioscience (London) earlier this year as a nonexecutive director, has been appointed chairman of the company, succeeding **Sir Aubrey Brocklebank**,

who will remain as a nonexecutive director. Dr. Glover formerly served as chief medical officer at Cambridge Antibody Technology.

InteKrin Therapeutics (Los Altos, CA, USA) has named **Linda Slanec Higgins** to the position of vice president, preclinical R&D. Dr. Higgins was most recently head of research at Scios.

Kevin Krenitsky has been appointed as CEO of BioServe (Beltsville, MD, USA). Dr. Krenitsky was most recently CEO of Parkway Clinical Laboratories, and prior to that served as senior vice president and division head at SeraCare Life Sciences’ genomics collaborative division.

Pfizer (New York) has announced the retirement of **John L. LaMattina**, a senior vice president of the company and president of global R&D, after a 30-year career with Pfizer. In addition, Pfizer also announced the resignation of its chief CFO, **Alan G. Levin**. Mr. Levin will remain in place until Pfizer hires a new CFO.

Valeant Pharmaceuticals (Aliso Viejo, CA, USA) has named **G. Mason Morfit** to its board of directors, filling an open board position for a term that expires at the 2008 annual stockholders meeting. Mr. Morfit is a partner with investment management firm ValueAct Capital, currently Valeant’s largest stockholder.

Medarex (Princeton, NJ, USA) has named **Howard H. Pien** as its president, CEO and member of the board of directors, succeeding **Irwin Lerner**, who has served as interim president and CEO since November 2006. Mr. Lerner will continue in his role as chairman of the board of Medarex. Mr. Pien served as president and CEO of Chiron until it was acquired by Novartis in April 2006. In addition, Mr. Pien has resigned his board membership with Cambridge,

Massachusetts-based ImmunoGen, as his new role with Medarex created a conflict of interest (ImmunoGen and Medarex both develop antibody-based anticancer therapeutics).

John Schembri has been named CFO of privately held BiPar Sciences (Brisbane, CA, USA). He comes to BiPar from Sirna Therapeutics, where he served as vice president of finance until the company was sold to Merck & Co. in December 2006.

Barrier Therapeutics (Princeton, NJ, USA) has announced the appointment of **Braham Shroot** to the newly created position of CSO. Dr. Shroot joins the company with more than 35 years of experience in dermatology drug development, most recently serving as CSO, vice president of R&D for DFB Pharmaceuticals, a specialty pharmaceutical company. Previously, he spent 13 years in various R&D positions with Galderma SA.



Ilypsa (Santa Clara, CA, USA) has promoted **Paul A. Stone** to the position of senior vice president, general counsel and chief patent counsel. Mr. Stone was formerly vice president and chief patent counsel

at Symyx Technologies, and originally joined Ilypsa in April 2005 as vice president, intellectual property and chief patent counsel.

Anne Wojcicki, founder of biotech startup 23andMe (Mountain View, CA, USA) was married last month to her long-time boyfriend, Google cofounder Sergey Brin. Dr. Wojcicki was a molecular biology researcher at the National Institutes of Health and the University of California, San Diego, before working as a consultant for San Francisco-based investment fund Passport Capital. Her new company aims to use genotyping technologies to provide consumers with genetic information for use in health, ancestry and genealogy studies. Mr. Brin has a net worth estimated at \$14 billion, placing him at No. 12 on *Forbes* magazine’s list of richest Americans last year.

Erratum: People

Nature Biotechnology 25, 692 (2007); published online 1 June 2007; corrected after print 8 August 2007

In the version of this article initially published, Anne Wojcicki was incorrectly referred to as Dr. Wojcicki rather than Ms. Wojcicki.

Corrigendum: Therapeutic targeting of a stem cell niche

Gregor B Adams, Roderick P Martin, Ian R Alley, Karissa T Chabner, Kenneth S Cohen, Laura M Calvi, Henry M Kronenberg & David T Scadden

Nature Biotechnology 25, 238–243 (2007); published online 21 January 2007; corrected after print 8 August 2007

In the version of this article initially published online 21 January 2007, the *y*-axes of Figures 1e, 2c and 2d are labeled incorrectly. They should be labeled “% CD45.1 in PB.” The error has been corrected for all versions of the article.